Introduction {#S1}
============

The large majority of human genes are transcribed as pre-mRNAs, containing non-coding (introns) and coding sequences (exons), that are processed by spliceosomal complexes to remove introns and produce mature mRNAs ([@B210]). The alternative removal of introns from pre-mRNAs and joining of exons into different mature transcripts enables the translation of multiple proteins from the transcription of a single gene ([@B28]). For this reason, the approximately 20,000 human genes are able to encode at least 100,000 different proteins ([@B256]).

Cell proteins generated by alternative splicing are selectively expressed in a tissue-specific and time-dependent manner and contribute to the regulation of numerous metabolic pathways involved in cell cycle control, differentiation and apoptosis ([@B14]). Aberrant splicing may cause the production of abnormal mRNA isoforms encoding mutated proteins with gain or loss of functions that are involved in neoplastic cell transformation, cancer development and metastasis ([@B175]).

The role of spliceosome complexes and splicing regulatory factors in cancer has been widely investigated ([@B175]). In particular, the snRNPs, the hnRNPs and the SR proteins have been shown to act either as oncoproteins or tumor suppressor proteins in different cancer types, including cervical neoplasia ([@B224]; [@B66]; [@B123]; [@B41]).

The aim of this review was to summarize the current studies on the role played by splicing factors in different cancer types with a particular focus on their peculiar activity in HPV-related cervical neoplasia. Indeed, in HPV infected cells the splicing factors are able to modulate the maturation either of cellular transcripts or of viral RNAs leading to the viral life cycle completion or production of viral and host cell transcripts encoding oncoproteins that cause transformation of cervical epithelium.

RNA Splicing Factors {#S2}
====================

The removal of introns from pre-mRNAs is a process catalyzed by two large ribonucleoprotein complexes, namely major and minor spliceosomes, in cooperation with numerous splicing factors ([@B94]; [@B181]). The major spliceosome, responsible for more than 99% of splicing reactions in human cells, is composed of five uridine-rich small nuclear RNAs (snRNA U1, U2, U4, U5, and U6) and over 100 snRNA associated proteins (snRNPs) that undergo complex conformational changes during the different phases of splicing reactions ([@B77]; [@B250]; [@B259]; [@B118]). On the other hand, the minor spliceosome, including the U5 snRNA as well as functional analogs of the major spliceosome snRNAs (U11, U12, U4atac and U6atac), catalyzes the splicing of the less abundant U12-type introns ([@B240]; [@B245]).

The splicing process consists of several sequential reactions involving recruitment of spliceosome components and interaction with *cis*-acting regulatory intronic sequences, such as the 5′ splice donor (SD) and 3′ splice acceptor (SA) sites, the intervening branch-point and the polypyrimidine tract ([@B1]; [@B257]). Briefly, the formation of an early spliceosome complex involves the interaction of the U1 snRNP with the 5′ splice site through the base pairing of the U1 snRNA component, the binding of the U2 accessory factor (U2AF) to the polypyrimidine region and the connection of U2AF to U1 through the bridging splicing factor SF1. Binding of U2 snRNA to the branch sequence and 3′ splice site facilitates the U1 and U2 snRNPs interaction and the formation of the spliceosome complex A. Then, the U4/U5/U6 snRNP trimer interacts with the U1 and U2 snRNPs forming the spliceosome complex B, which releases the U1 and U4 snRNPs and becomes activated (complex C) ([@B250]). The active spliceosome causes the final exclusion of the intron through: (1) the cleavage of the intron 5′-end; (2) the formation of a lariat (the 5′-end of the intron binds to the branch point); (3) the cleavage of the intron 3′-end; (4) the release of the lariat/U2/U5/U6 complex; and (5) the joining of exons ([@B136]; [@B181]) ([Figure 1](#F1){ref-type="fig"}).

![Steps of the splicing process. The snRNP U1, SF1 and U2AF bind to the intron 5′-end SD site, to an intronic branch point site (A) and to the intron 3′-end SA site, respectively. The U2 displaces SF1 and the U4/U5/U6 snRNPs trimer interacts with snRNPs U1 and U2 causing U1 and U4 release. The activated spliceosome catalyzes the cleavage of the intron 5′-end, the formation of a lariat, the intron the cleavage of the intron 3′-end, the release of the lariat/U2/U5/U6 complex release and joining of exons ([@B210]). Exons are defined as "E"; the intron is represented as a black solid line.](fcell-08-00474-g001){#F1}

The alternative recognition of differential splice donor and acceptor sites allows the production of several mRNA isoforms according to five different figures: (1) the exon is totally or partially skipped; (2) mutually exclusive exons are included; (3) introns are retained; (4) alternative splice donor; or (5) splice acceptor sites are selectively chosen leading to the production of exons with different lengths ([@B136]; [@B256]) ([Figure 2](#F2){ref-type="fig"}).

![Mechanisms of alternative splicing. The spliceosome generates distinct mRNA isoforms by alternative usage of splice donor (SD) and acceptor (SA) sites, located at the 5′ and 3′ end of introns, respectively. The splicing products include: (I) exon skipping (the partial or total removal of exons), (II) inclusion of mutually exclusive exons, (III) intron retention and the use of alternative (IV) SD or (V) SA sites ([@B14]). In the figure, black solid lines represent introns; black and red dashed lines represent alternative splicing mechanisms. Exons are indicated as "E" and introns are indicated as "I."](fcell-08-00474-g002){#F2}

The fine tuning of pre-mRNA maturation is regulated by *trans*-acting splicing factors including hnRNPs, that generally inhibit the splicing by binding to exonic (ESSs) or intronic splicing silencers (ISSs) sequences, and SR proteins that typically activate the splicing by interacting with exonic (ESEs) and intronic (ISEs) splicing enhancers ([@B257]; [@B37]) ([Figure 3](#F3){ref-type="fig"}).

![Regulation of alternative splicing. Alternative splicing is finely regulated by trans-acting hnRNPs and SRSFs protein families. The hnRNPs generally bind exonic (ESSs) and intronic splicing silencers (ISSs), antagonize SRs activity and inhibit spliceosome assembly on the splicing sites (red lines). The SRSFs bind to exonic (ESEs) and intronic (ISEs) splicing enhancers and increase the splicing efficiency by favoring the spliceosome recruitment and assembly on the splicing sites (green lines) ([@B37]; [@B256]).](fcell-08-00474-g003){#F3}

The hnRNPs are a protein family comprising 20 major RNA-binding proteins that contain a RRM, a quasi-RRM domain and a K Homology (KH) domain binding to pre-mRNA sequences as well as a glycine-rich domain interacting with other hnRNPs ([@B27]). The canonical function of hnRNPs is the inhibition of splicing reactions through their binding to cognate sites and repression of either the assembly of the spliceosome complex on the 5′-SD and 3′-SA sites or the recruitment of SR proteins on ESEs and ISEs following multimerization along exons or by looping out entire exons ([@B170]; [@B89]; [@B65]; [@B246]) ([Figure 3](#F3){ref-type="fig"}). On the other hand, some hnRNPs have been shown to promote splicing through their interaction with ISE sequences containing G triplets. Indeed, hnRNP A1 and hnRNP F have been recognized to bind a AGGGA sequence in the 5′ GA-rich enhancer within the intron 10 of the insulin receptor gene (INSR) transcript as well as similar motifs located at the 3′ end of the same intron and to regulate the skipping or the inclusion of exon 11 causing the differential expression of the insulin receptor A or B isoforms, respectively ([@B237]).

Most of the hnRNPs, including hnRNP A1/A2, hnRNP B1/B2, hnRNP E, hnRNP J, and hnRNP K, are localized to the nucleus and after homomeric and heteromeric complexes formation they shuttle to the cytoplasm via the transportins binding ([@B217]; [@B156]; [@B89]). On the other hand, hnRNP C and hnRNP U possess a nuclear retention sequence that inhibits transfer to the cytoplasm ([@B167]; [@B156]). Post-translational modifications of hnRNPs, such as serine and threonine phosphorylation, arginines methylation, SUMOylation and ubiquitination, affect their sub-cellular localization and modulate positively or negatively their activity ([@B135]; [@B78]; [@B164]; [@B254]). For instance, the ERK kinase was shown to phosphorylate hnRNP K serines 284 and 353 in response to stress stimuli and to cause cytoplasmic accumulation and inhibition of hnRNP K-mediated translation in HeLa cells ([@B100]). In addition, the hnRNPs are able to modulate also the mRNA stability, capping, transport and poly-adenylation as well as to regulate the telomeres maintenance and chromatin organization ([@B101]; [@B89]).

The SR proteins family includes twelve serine-arginine rich splicing factors (SRSF1 to 12) characterized by canonical RRM, that interact with the ESE and ISE elements, and C-terminal serine-arginine repeats, which facilitate the recruitment of the spliceosome components to the splice sites (i.e., the binding of U1 to the 5′-SD site) and promote splicing processes ([@B151]; [@B208]; [@B23]; [@B106]) ([Figure 3](#F3){ref-type="fig"}). In a few cases the SR proteins have been shown to bind silencer elements and to repress splicing ([@B116]; [@B212]; [@B208]). For example, SRSF1 (SF2/ASF), SRSF4 (SRp75), SRSF5 (SRp40), and SRSF6 (SRp55) are able to bind an ISS located in the intron 9 of the CFTR transcript and to skip the exon 9 causing the production of a nonfunctional protein associated with cystic fibrosis development ([@B178]).

The localization of SR proteins is regulated by dynamic serine-arginine repeats phosphorylation/dephosphorylation cycles that also modify their protein--protein interaction and functional activities ([@B289]; [@B146]). For example, the SRSF1, SRSF3 (SRp20), and SRSF7 (9G8) phosphorylated proteins are bound and shuttled by transportin SR2 from the cytoplasm to the nucleus ([@B128], [@B129]). The serine-arginine rich proteins are specifically phosphorylated by the serine/arginine-protein kinases (SRPKs) and the Cdc2-like kinase/Ser-Thr-Tyr (Clk/Sty) kinases ([@B47]; [@B91]). The SRPKs are constitutively active in normal cells and localize either in the cytoplasm or into the nucleus ([@B91]). The nuclear kinase CLK1 has been shown to phosphorylate the RS2 domain of SRSF1 and to cause the re-localization from speckles to the nucleoplasm ([@B11]). In particular conditions, the SR proteins are phosphorylated by other kinases such as topoisomerase 1 (TOPO1), which becomes active in response to extra-cellular stimuli, and by Akt kinase and MAP kinases (MAPKs) that are constitutively active in cancer cells ([@B199]; [@B169]). The SRSFs, similarly to hnRNPs, have also a variety of non-canonical activities related to the stability, export and translation of mRNAs as well as to the chromatin remodeling, nucleolar stress response, genome stability and cell cycle regulation ([@B104]).

Deregulation of the Splicing Machinery in Cancer {#S3}
================================================

Several studies demonstrated that deregulation of constitutive and alternative splicing plays a crucial role in carcinogenesis and could be considered a novel cancer hallmark ([@B175]; [@B68]; [@B252]; [@B276]; [@B33]). Indeed, recent transcriptome sequencing analyses demonstrated that splicing factors expression is commonly deregulated in a multitude of cancer types and is associated with alterations of the tissue-specific transcripts as well as modification of protein--protein interactions ([@B25]; [@B216]).

Characterization of known transcripts from RNA-seq data of 4,542 tumor samples from 11 cancer types recorded in TCGA revealed the presence of 8,122 switches in the RNA isoforms encoded by 6,442 genes, the most common being RAC1 gaining an extra Ras domain and TP53 losing coding capacity ([@B44]). Such changes were found mainly associated with alterations in apoptosis, ubiquitin-mediated proteolysis, ERBB-signaling, RNA transcription and splicing pathways ([@B44]). In addition, the comprehensive analysis of whole exome sequencing and RNA-seq data of 8,705 tumor samples and 640 normal control tissues from 32 cancer types, including cervical cancer, showed approximately 251,000 new exon--exon junctions in tumors (around 930 per sample), of which 18,000 were recurrent events detected in at least 100 samples ([@B112]). Such novel exon--exon junctions were predicted to produce "neoantigens" and to affect the immune response ([@B112]). [@B52] extended the analysis of exon--exon junctions to 10,549 tumor samples across 33 TCGA cancer types and observed that more than 50% of new junctions were not shared among cancer samples. Importantly, in cervical cancer they identified a total of 14,086,434 exon--exon junctions of which 2,263,326 were specific to cervical cancer ([@B52]).

Several mechanisms are responsible for aberrant splicing processes in human cancers. First, the uncontrolled overexpression of splicing factors may cause anomalous splicing events in tumors ([@B234]). The up-regulation of hnRNPs and SRSFs has shown to be commonly caused by gene rearrangements and copy number variations in a variety of cancer types ([@B211]). For example, the HNRNPA2B1 gene was found amplified in glioblastoma and its copy number was demonstrated to be inversely correlated with patients survival ([@B92]). Moreover, the amplification of the chromosome 17q23 and chromosome 6p21 regions has been shown to cause the overexpression of SRSF1 in breast cancer and SRSF3 in lung and cervical carcinoma, respectively ([@B185]; [@B108]).

The expression of hnRNP A1, hnRNP A2 and hnRNP I (also known as polypyrimidine tract binding protein, PTB) was demonstrated to be trans-activated by Myc oncoprotein. Specifically, the Myc mediated up-regulation of hnRNP A1, hnRNP A2 and hnRNP I induces the production of the pyruvate kinase embryonic isoform PKM2 and the activation of the aerobic glycolysis in different cancer cells ([@B43]; [@B51]; [@B35]). Myc was also demonstrated to bind E-boxes in the SRSF1 promoter and to transactivate the SRSF1 overexpression that cause production of MKNK2 +13B and TEAD1 +5 isoforms and enhanced proliferation of lung cancer cells ([@B50]).

Altered processing of splicing regulator transcripts represents a further mechanism of abnormal pre-mRNA maturation ([@B49]). For instance, knockdown experiments of S6K2 kinase, that phosphorylates the serine^6^ residue in hnRNP A1 protein, caused enhanced production of the PKM2 isoform and increased glycolysis in colorectal cancer cells ([@B233]). The overexpression of SRPK1 causes the hyper-phosphorylation of SRSF1, leading to increased production of Rac1b, an oncogenic variant of the GTPase Rac1 signaling protein that promotes survival and proliferation of colorectal cancer cells ([@B93]; [@B186]). The overexpression of Clk2 kinase was also shown to sustain cell growth in breast cancer, while its silencing was demonstrated to reduce the SRSF1 phosphorylation and to induce the production of the ENAH isoform, which is typical of the mesenchymal phenotype and associated with tumor invasion and metastasis ([@B269]). *In vitro* studies demonstrated that the up-regulation of the NEK2 kinase promotes the production of the anti-apoptotic BCL-X~L~ variant through the anomalous phosphorylation of SRSF1 ([@B168]). In addition, the PI3K/Akt signaling pathway, constitutively activated by mutated EGFR, leads to SRSF1 hyper-phosphorylation and consequent reduction of the anti-apoptotic isoform Casp-9b in lung cancer ([@B215]).

Other post-translational modifications, such as acetylation and ubiquitination, are important modulators of splicing factors activity. For example, the hyper-acetylation of hnRNP A1 induced by high glucose levels in hepatocellular carcinoma cells promotes the production of the PKM2 variant and consequent enhancement of glucose metabolism as well as transcription of genes responsible for cell proliferation and growth, such as GLUT1, LDHA, PDK1, CCND1, and MYC ([@B266]). In addition, the hyper-acetylation of SRSF5 by Tip60 acetyl-transferase causes the production of the CCAR1 isoform S, which favors tumor growth by promoting glucose consumption and acetyl-CoA production ([@B38]). On the other hand, the hypo-acetylation and consequent degradation of SRSF5 by the Smurf1 ubiquitin ligase causes CCAR1S reduction under low intracellular glucose levels ([@B38]).

The hyper-*O*-GlcNAcylation of hnRNP-K in cholangiocarcinoma cells induces its translocation to the nucleus, where it drives the expression of genes involved in the extracellular matrix composition, cell movement, angiogenesis and epithelial mesenchymal transition, such as CCK, MMP3, PTGS2, and CTGF as well as CCND1 and XIAP ([@B85]; [@B188]). The overexpression of the SUMO1 was shown to cause the sumoylation of hnRNP K and increased *c-Myc* transcription associated with cell proliferation in Burkitt lymphoma ([@B230]).

Recurrent somatic mutations in splicing factors encoding genes have also been shown to affect the splicing processes in cancer ([@B115]; [@B258]; [@B234]). Specifically, oncogenic driver mutations have been identified in 119 genes encoding for splicing factors in a variety of tumors ([@B207]). For instance, point mutations and deletions in the HNRNPK gene, causing hnRNP K down-regulation, have been suggested to have a role in the development of acute myeloid leukemia ([@B235]; [@B83]). Moreover, hotspot mutations in the SRSF2 gene, such as P95H, change the binding properties of the SRSF2 protein and cause genome-wide splicing network alteration and aberrant maturation of different hnRNPs, including HNRNPA2B1, HNRNPM, HNRNPH1, and HNRNPH3, especially in myelodysplastic syndromes ([@B125]; [@B10]; [@B12]; [@B142]; [@B152]).

Moreover, nucleotide changes within the exonic or intronic *cis*-acting splicing factors binding motifs may result in the disruption or creation of binding sites and aberrant splicing reactions ([@B255]; [@B225]). A recent whole-exome and transcriptome comprehensive study including 31 cancer types identified 14,438 splicing-associated variants, most of which were shown to disrupt donor and acceptor sites and to cause exon skipping, intron retention and alternative 5′ or 3′ splicing site usage particularly in TP53 and GATA3 genes ([@B213]).

Additionally, non-coding RNAs, such as miRNAs, are able to regulate splicing and transcription both in normal and tumor tissues for their ability to target the 3′-UTR of hnRNPs and SRSFs mRNAs ([@B7]). For instance, the miR-15a-5p and miR-25-3p have been described as negative regulators of hnRNP A1 expression, required for the maturation of miR-18a-3p, that in turn inhibits the K-RAS oncogene in ovarian cancer ([@B197]). Besides, miR-183-5p and miR-200c-3p in renal cancer as well as miR-193a-3p in gastric cancer have been demonstrated to target the SRSF2 (SC35) 3′-UTR mRNA, affecting the maturation of several pre-mRNAs involved in the apoptosis ([@B219]; [@B134]).

On the other hand, the hnRNP and SRSF proteins are able to control directly or indirectly the expression of several miRNAs and other non-coding RNAs involved in cancer development ([@B194]). Indeed, the hnRNP A1 has been shown to interact with pri-miR-18a conserved terminal loop and to induce a relaxation in the stem loop that facilitates the cleavage by Drosha and production of mature miR-18a in prostate, esophageal, pancreatic, hepatocellular, and colorectal cancer ([@B99]; [@B124]; [@B126]). Moreover, the hnRNP D reduces the Dicer1 levels by targeting the 3′-UTR of DICER1 mRNA, causing down-regulation of tumor suppressor miR-122 and increased viability of PLC/PRF/5 hepatoma as well as Huh7 liver derived cell lines ([@B263]). Among SRSF proteins, the SRSF3 was demonstrated to enhance the processing of miR-16-1, miR-30a and miR-223 through the binding of a CNNC motif located 17-18 nucleotides downstream the Drosha cleavage signal ([@B13]).

Several hnRNPs, especially hnRNP K, are also able to modulate the expression of genes involved in the carcinogenic processes through their interaction with lncRNAs ([@B232]). In particular, [@B137] observed that linc00460 was overexpressed in non-small cell lung tumors and was able to interact with hnRNP K promoting migration and invasion of H460 and A549 human lung cancer cell lines. Furthermore, the analysis of RNA binding proteins-lncRNAs interaction network in the POSTAR2 database and co-immunoprecipitation experiments showed that SRSF1 was able to interact with and to stabilize the lncRNA NEAT1 causing increased cell proliferation in U87MG glioma cell line ([@B288]).

Recently, hnRNPs have also been demonstrated to modulate the production of circular RNAs ([@B127]). Specifically, the profiling of circular RNAs transcriptome in LNCaP prostate cancer cells expressing HNRNPL compared to HNRNPL-knockdown cells revealed the differential production of circ-PRKAR1B, circ-ZMIZ1, circ-FOXJ3, and circ-CCNY that have been suggested to be involved in prostate cancer development ([@B73]).

Oncogenic Functions of hnRNPs and SRSFs {#S3.SS1}
---------------------------------------

Several hnRNP and SRSF proteins have been demonstrated to be overexpressed in tumors and to possess multiple oncogenic functions ([@B68]) ([Table 1](#T1){ref-type="table"}). In particular, hnRNP A1 is upregulated in lung cancer and its silencing in lung cancer cell line A549 causes cell cycle arrest in G0/G1 phase ([@B145]). The hnRNP A1 expression enhances the production of a cyclin dependent kinase 2 (CDK2) isoform, characterized by the exon 5 retention, that promotes cell growth, while its inhibition causes the cell cycle arrest at the G2/M phase in oral squamous cancer cell lines ([@B270]). The overexpression of hnRNP A1 in gastric cancer and hnRNP A2/B1 in lung cancer has been shown to enhance the metastatic potential of tumor cells by inducing a shift from the expression of epithelial markers (i.e., E-cadherin) to mesenchymal markers (i.e., vimentin and snail) phenotype ([@B22]; [@B241]; [@B39]). The hnRNP A1 also mediates the production of the CD44v6 isoform, associated with larger tumor size, microvascular invasion and tumor recurrence in hepatocellular carcinoma patients ([@B290]).

###### 

Splicing factors and regulated oncogenic processes: physiological functions and oncogenic activities in different cancer types and cell lines.

  Splicing factors (aliases)   Regulated processes                                                                                          Oncogenic activities                                                                                                 Pathologic mechanism   Experimental model   Cancer types and cell lines           References
  ---------------------------- ------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------- ---------------------- -------------------- ------------------------------------- ------------
  **hnRNPs**                                                                                                                                                                                                                                                                                                                                       
  hnRNP A1                     Splicing, mRNA export and stability, telomeres maintenance, translation                                      Induction of cell growth by regulation of CDK2 exon 5 alternative splicing                                           OE                     KD                   CAL 27 cell line                      [@B270]
  hnRNP A2/B1                  Splicing, mRNA localization and stability                                                                    Induction of EMT markers expression                                                                                  OE                     OE, KD               A549 cell line                        [@B241]
  hnRNP C1/C2                  Splicing, mRNA transport and stabilization, translation                                                      Maturation of miR-21, down-regulation of PDCD4, reduction of apoptosis, increase of proliferation and invasiveness   OE                     KD                   T98G cell line                        [@B182]
  hnRNP D                      Telomeres maintenance, development, apoptosis, DNA recombination, mRNA decay                                 Up-regulation of GCH1, promoting cell proliferation and colony formation                                             OE                     KD                   Eca-109 cell line                     [@B87]
  hnRNP E1                     Splicing, mRNA stability, transcription, translation                                                         Production of integrin β1A isoform promoting lymph node and hepatic metastases                                       OE                     OE, KD               Pancreatic cancer                     [@B110]
  hnRNP E2                     Splicing, mRNA stability, transcription, translation                                                         Up-regulation of CDK2 stimulating cell proliferation                                                                 OE                     KD                   HGC-27 and MKN-45 cell lines          [@B34]
  hnRNP K                      Splicing, transcription, translation, mRNA stability                                                         Enhancement of cell migration and metastatization by up-regulation of MMP3, MMP10, PTGS2, ITGA6, CTGF, and RASA1     OE                     OE                   U2OS cell line                        [@B85]
  hnRNP L                      Splicing, mRNA export and stability, riboswitch                                                              Activation of MAPK signaling and inhibition of caspase-3, -6, and -9                                                 OE                     OE, KD               UM-UC-3, EJ, T24 and RT4 cell lines   [@B150]
  hnRNP M                      Splicing                                                                                                     Production of CD44 standard isoform, associated with poor outcome and metastases                                     OE                     OE                   Breast cancer                         [@B231]
  **SRSFs**                                                                                                                                                                                                                                                                                                                                        
  SRSF1 (SF2/ASF)              Splicing, mRNA export, mRNA NMD, nucleolar stress response, miRNA processing, mTOR activation, translation   Production of cyclin D1b isoform promoting cell proliferation                                                        OE                     KD                   Prostate cancer                       [@B174]
  SRSF2 (SC35)                 Splicing, mRNA export, transcription                                                                         Production of GCH1-L and STK39-L isoforms increasing cell growth and colony forming efficiency                       OE                     OE, KD               Huh7 cell lines                       [@B149]
  SRSF3 (SRp20)                Splicing, translation, mRNA export and decay                                                                 Inhibition of apoptosis by down-regulating PDCD4                                                                     OE                     KD                   SW480 and U2OS cell lines             [@B120]
  SRSF5 (SRp40)                Splicing, translation                                                                                        Induction of MCM2 and MCM4 expression, enhancing cell proliferation and colony formation efficiency                  OE                     KD                   CAL 27 and SCC-9 cell line            [@B267]
  SRSF6 (SRp55)                Splicing                                                                                                     Regulation of CRH-R1 production and cell proliferation                                                               OE                     KD                   Breast cancer                         [@B130]
  SRSF7 (9G8)                  Splicing, mRNA transport, translation                                                                        Production of exon 6 deleted Fas variant promoting cell survival                                                     OE                     KD                   HCT116 and A549 cell lines            [@B80]
  SRSF9 (SRp30c)               Splicing, RNA editing                                                                                        Enhanced expression of β-catenin                                                                                     OE                     OE, KD               HCT116 and SW620 cell lines           [@B79]
  SRSF10 (SRp38)               Splicing                                                                                                     Production of BCLAF1-L variant promoting cell proliferation and growth                                               OE                     KD                   RKO and HCT116 cell lines             [@B287]
  **Others**                                                                                                                                                                                                                                                                                                                                       
  Tra2β                        Splicing                                                                                                     Production of NASP-T isoform enhancing the HSPA2 ATPase, which increases proliferation and reduced apoptosis         OE                     KD                   PC-3 cell line                        [@B6]
  Sam68                        Splicing, translation, transcription, mRNA export                                                            Production of constitutively active androgen receptor V7 variant                                                     OE                     OE, KD               LNCaP cell line                       [@B226]

OE, overexpression; KD, knock-down.

The hnRNP D, that is overexpression in Eca-109 esophageal cancer cell line, has been recognized to bind the 3′-UTR AU-rich motifs of GTP cyclohydrolase (GCH1) transcripts causing GCH1 overexpression and enhanced cell proliferation and colony formation ([@B87]). Moreover, the hnRNP D protein can specifically bind to single-stranded d(TTAGGG)n human telomeric repeats through its C-terminal binding domain (BD2), thus impeding the formation of a DNA-quadruplex while favoring telomeres elongation and maintenance ([@B70]). The ectopic expression of p42 and/or p45 hnRNP D isoforms in hnRNP D-deleted mouse embryonic fibroblasts demonstrated that such isoforms are able to bind TERT promoter and to strongly transactivate TERT expression, thus reducing cell senescence ([@B190]).

The hnRNP E1 plays a major role in the production of integrin β1A isoform, whose expression has been found to correlate with lymph node and hepatic metastasis of pancreatic cancer, while the upregulation of hnRNP E2 was shown to promote the expression of CDK2 causing increased proliferation of gastric cancer cells ([@B110]; [@B34]).

The hnRNP K expression has been demonstrated to enhance the transcription of genes involved in the extracellular matrix composition, especially MMP3 and MMP10, as well as of genes responsible for cell motility, such as PTGS2 and ITGA6, and angiogenesis, like CTGF and RASA1 ([@B85]).

The hnRNP L was shown to activate MAPK signaling while inhibiting caspase-3, -6 and -9 in bladder cancer cells as well as to suppress p53 expression and bcl-2/caspase-9/3 signaling via TP53 mRNA and bcl-2 binding, respectively, in prostate cancer cells ([@B150]; [@B286]).

Overexpressed hnRNP M has been demonstrated to mediate the reduction of CD44v6 and increase of the CD44 standard isoform, that is associated with shorter overall survival and axillary lymph node metastases in breast cancer patients ([@B231]).

Among the SRSFs family, the SRSF1 gene was the first to be identified as a proto-oncogene with overexpression in colon, thyroid, small intestine, kidney and lung tumors ([@B117]). In particular, [@B117] showed that SRSF1 regulates the alternative splicing of the tumor suppressor BIN1 and kinases MNK2 and S6K1 causing the production of a BIN1 isoform lacking tumor-suppressor activity, a MNK2 isoform promoting MAP kinase-independent eIF4E phosphorylation, and an oncogenic S6K1 isoform in transformed NIH 3T3 and Rat1 cell lines. The overexpression of SRSF1 was also shown to increase cell proliferation through the production of the exon 5 lacking-variant cyclin D1b in prostate cancer and to induce epithelial mesenchymal transition by stimulating the production of the ΔRon variant in breast cancer ([@B90]; [@B174]).

Thereafter, several other SR proteins have been demonstrated to possess oncogenic activities in several tumor types ([Table 1](#T1){ref-type="table"}). For example, the knockdown of SRSF2 in Huh7 liver cancer cell line revealed 966 splicing alterations in cancer-related gene transcripts, favoring the production of oncogenic mRNA variants, such as the GCH1-L and STK39-L isoforms, that are involved in cell-cycle control and DNA repair ([@B149]).

The overexpression of SRSF3 into "normal" lung cell line WI-38 was able to modify the alternative splicing of the interleukin enhancer-binding factor 3 (ILF3) pre-mRNA and to increase the production of isoform-1 and isoform-2, both required for cell proliferation ([@B107]). Moreover, SRSF3 is able to deregulate the apoptotic pathway by binding to 5′-UTR of PDCD4 mRNA and by inhibiting the expression of the PDCD4, a critical suppressor of apoptosis ([@B120]).

The SRSF 5-7 proteins are particularly abundant in small cell lung cancer and associated with pleural metastasis ([@B119]). The SRSF5 enhances the expression of the MCM family members MCM2 and MCM4, that are involved in the initiation and elongation processes of DNA replication, as well as cell growth and colony formation when transfected in CAL 27 and SCC-9 oral squamous cell carcinoma cell lines ([@B267]). The SRSF6 is involved in the abnormal alternative splicing of the corticotropin-releasing hormone receptor type 1 (CRH-R1) causing indirect perturbation of oncogenic kinases, such as p38 MAPK, Akt and GSK3β, and accumulation of β-catenin in breast cancer ([@B130]). Knockdown experiments of SRSF7 in HCT116 colon and A549 lung cancer cell lines revealed the production of an exon 6-lacking isoform of the Fas receptor mRNA, that promotes cell survival ([@B80]).

The SRSF9 protein is frequently overexpressed in glioblastoma, colon adenocarcinoma, squamous cell lung carcinoma and malignant melanoma ([@B79]). The enhanced co-expression of SRSF9 and SRSF1 has been shown to promote tumourigenesis by Wnt signaling activation in a mTOR-dependent manner and to enhance translation of β-catenin mRNA ([@B79]).

The SRSF10 (SRp38) is an atypical SR protein acting as a potent general splicing repressor in its dephosphorylated form and as a sequence-specific splicing activator in its phosphorylated status ([@B74]). It was shown to mediate the expression of the BCLAF1 exon5a isoform (BCLAF1-L) that promotes cell proliferation and growth in colon cancer cell lines RKO and HCT116 ([@B287]).

Other Oncogenic Splicing Factors {#S3.SS2}
--------------------------------

Splicing factors other than hnRNPs and SR family members, such as Tra2β, Brm and Sam68, have been also demonstrated to play a role in cancer development. The Tra2β is an SR-like protein characterized by a double N- and C-terminal RS domains that is able to promote alternative exons inclusion in a dose-dependent manner ([@B236]; [@B227]; [@B249]; [@B98]; [@B69]). The TRA2B gene is amplified in several tumor types, including lung, head and neck, ovary, stomach and uterus cancers ([@B82]; [@B84]). Increased levels of Tra2β promote the production of the NASP-T isoform, enhances the ATPase activity of heat shock protein HSPA2 and causes increased proliferation as well as reduced apoptosis in PC-3 prostate cancer cell line ([@B6]; [@B18]).

The Brm is a member of SWI/SNF (mating-type switch/sucrose non-fermentable) proteins family, involved in chromatin structure remodeling and DNA-damage response ([@B229]; [@B196]; [@B218]). The Brm factor interacts with U1, U3, and U5 snRNPs of the major spliceosome complex and favors the inclusion of alternative exons in gene transcripts involved in carcinogenesis ([@B218]; [@B192]). In particular, the overexpression of BRM gene enhances the inclusion of exon 9 in the E-caderin mRNA in the MCF-7 human breast cancer cell line, while the Brm knockdown promotes the production of a cyclin D1b variant lacking exon 27 in Caco2 cell lines ([@B16]).

The Sam68 is the prototypic member of the STAR family proteins that regulates alternative splicing and RNA processing in response to signaling pathways ([@B242]). This factor contains a 200 amino acids long domain (GRP33/SAM68/GLD-1, GSG) that bind to RNA sequences as well as C-terminal six-proline-rich and tyrosine-rich sequences that interact with SRC homology 2 (SH2) and 3 (SH3) domains of BRK, FYN and Itk/Tec/BTK kinases ([@B8]; [@B54]; [@B184]; [@B165]). Sam68 was found overexpressed and associated with poor prognosis in several cancer types, including non-small cell lung carcinoma and breast, hepatocellular, renal, prostate and gastric cancers ([@B26]; [@B277], [@B278], [@B274]; [@B223]; [@B264]). In addition, it was shown to modulate the splicing of transcripts encoded by genes involved in oncogenic pathways ([@B19]). In particular, [@B183] demonstrated that ERK-phosphorylated Sam68 was able to inhibit the U1 snRNP recruitment to the intron-exon 4 junction of CCND1 mRNA in the presence of the rs9344 (870A\>G) polymorphism, thus favoring the production of the cyclin D1b. Moreover, Sam68 was also demonstrated to bind an ESE located near the cryptic exon 3b 3′ splice site of the androgen receptor mRNA, promoting the inclusion of exon 3b in the transcript and its translation into the androgen receptor V7 variant in the LNCaP prostate cancer cell line ([@B226]).

Alternative Splicing in HPV-Related Cervical Neoplasia {#S4}
======================================================

The cell splicing factors contribute to cervical neoplasia by two distinct but converging mechanisms: (1) by mediating the differential maturation of HPV RNA isoforms, required for virus replication and for viral oncoprotein expression; and (2) by promoting the production of cell mRNA variants and proteins with oncogenic functions that may have roles in cervical neoplasia development and in the progression to later stages of cervical carcinogenesis ([@B160]; [@B111]; [@B175]) ([Table 2](#T2){ref-type="table"}).

###### 

Splicing factors that have been recognized to affect splicing of HPV16 and host cell transcripts in cervical cancer.

  Splicing factors (aliases)   Cancer hallmarks                                                                                                                          References   HPV16 mRNAs                                                                                                                                                                                    References
  ---------------------------- ----------------------------------------------------------------------------------------------------------------------------------------- ------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------
  **hnRNPs**                                                                                                                                                                                                                                                                                                                                                                         
  hnRNP A1                     Regulation of apoptosis by procaspase-3 and PARP cleavage                                                                                 [@B187]      Production of E6\*I/E7 isoform, inhibition of SA5639 and of L1 mRNAs production                                                                                                                [@B42]; [@B198]
  hnRNP A2/B1                  Up-regulation of p21 and p27, enhanced cleavage of caspase-3, down-regulation of p-Akt                                                    [@B209]      Production of E6\*I/E7 isoform, inhibition of SA5639 and of L1 mRNAs production                                                                                                                [@B198]; [@B139]
  hnRNP C                      --                                                                                                                                        --           Activation of SD3632 and of L1 mRNAs production                                                                                                                                                [@B55]
  hnRNP D                      --                                                                                                                                        --           Inhibition of SD3632 and of late mRNAs production                                                                                                                                              [@B139]
  hnRNP E1/E2                  --                                                                                                                                        --           Inhibition of L2 mRNAs production                                                                                                                                                              [@B32]
  hnRNP F                      Production of ENOX2 exon 4 minus splice variant, promoting cell growth                                                                    [@B239]      --                                                                                                                                                                                             --
  hnRNP G                      --                                                                                                                                        --           Activation of SA3358 and late mRNAs production                                                                                                                                                 [@B271]
  hnRNP H                      --                                                                                                                                        --           Activation of pA~E~ and inhibition of late mRNAs production                                                                                                                                    [@B172]; [@B285]
  hnRNP I (PTB)                Regulation of cell proliferation, anchorage-independent growth and invasiveness                                                           [@B253]      Inhibition of pA~L~, activation of SD3632 and of late mRNAs production                                                                                                                         [@B222]
  hnRNP K                      Regulation of cell cycle                                                                                                                  [@B148]      Inhibition of L2 mRNAs production                                                                                                                                                              [@B45]
  hnRNP L                      --                                                                                                                                        --           Activation of SA3358 and pA~E~, inhibition of late mRNAs production                                                                                                                            [@B114]
  hnRNP P2                     Promotion of EMT and cell proliferation                                                                                                   [@B291]      --                                                                                                                                                                                             --
  **SRSFs**                                                                                                                                                                                                                                                                                                                                                                          
  SRSF1 (ASF/SF2)              Up-regulation of caspase 9a/9b ratio                                                                                                      [@B214]      Activation of SA3358 and of E6/E7 mRNA production, production of E4, E5, L1, and L2 mRNAs, inhibition of SA3632 and of late mRNAs production, inhibition of SA2709 and of E2 mRNA production   [@B200]; [@B221]; [@B138]; [@B155]
  SRSF2 (SC35)                 Reduction of apoptosis, increased anchorage-independent growth, cell cycle progression                                                    [@B155]      Production of E6/E7 mRNAs                                                                                                                                                                      [@B155]
  SRSF3 (SRp30)                Enhancement of cell proliferation                                                                                                         [@B108]      Production of E6/E7 mRNA and of E4/L1 mRNA, inhibition of SA3358 and of late mRNAs production                                                                                                  [@B200]; [@B155]; [@B122]
  SRSF9 (SRp30c)               Increased colony formation and proliferation, reduced apoptosis                                                                           [@B272]      Inhibition of SA3358, activation of SA5639 and of late mRNAs production                                                                                                                        [@B220]
  SRSF10 (SRp38)               Increased cell proliferation and tumor growth, production of mIL1RAP, activation of IL-1β signal transduction and NF-κB, immune evasion   [@B144]      --                                                                                                                                                                                             --
  SRSF11 (SRp54)               Telomeres elongation                                                                                                                      [@B132]      --                                                                                                                                                                                             --
  **Others**                                                                                                                                                                                                                                                                                                                                                                         
  Tra2β                        Increased lymph node metastatization, tumor grade, size and invasion depth                                                                [@B82]       --                                                                                                                                                                                             --
  Brm                          Production of pro-metastatic CD44v5 in cooperation with Sam68                                                                             [@B16]       Production of E6/E7 mRNA                                                                                                                                                                       [@B198]
  Sam68                        Increased lymph node metastases and EMT, production of CD44v5 and of anti-apoptotic DEx3 variant                                          [@B141]      Production of E6/E7 mRNA                                                                                                                                                                       [@B198]

HPV Infection and Viral Gene Expression {#S4.SS1}
---------------------------------------

Persistent infection with high-risk HPVs, most commonly HPV16 and HPV18, is the main risk factor for development of almost all cases of cervical cancer ([@B60]; [@B204]), and of significant fraction of penile and anal cancers ([@B163]), vulvar cancer ([@B191]), as well as tumors of the upper respiratory tract, including head and neck cancers ([@B29]). Most HPV infections of the cervix are successfully cleared by the host immune system in 2--3 years, but in several cases the infection may persist over the time leading to CIN graded 1 to 3 that eventually evolve during a long lasting period in invasive cervical carcinoma ([@B154]; [@B64]; [@B177]).

HPV genomes are double stranded circular DNAs of approximately 8000 bp which can be divided into three main regions: (1) the early region, containing the E1, E2, E3, E4, E5, E6 and E7 ORFs, encoding for regulatory proteins; (2) the late region, including L1 and L2 ORFs, encoding for viral capsid proteins and 3) the LCR, comprising the origin of replication and multiple transcription factor binding sites ([@B283]; [@B61]). An early polyadenylation site (pA~E~) is located between the early and the late ORFs, while a late polyadenylation site (pA~L~) is positioned between the late genes and the LCR sequence ([@B283]; [@B95]) ([Figure 4](#F4){ref-type="fig"}).

![A schematic representation of the HPV16 genome and transcripts. The scheme is based on the HPV episteme ([@B248]). **(A)** The P97 derived early mRNAs are polyadenylated at the early polyadenylation site (pAE). The P670 and PE8 derived late mRNAs are polyadenylated at the late polyadenylation site (pAL). Both the early **(B)** and late **(C)** transcripts are polycistronic and subjected to alternative splicing ([@B283]; [@B95]; [@B97]). The donor (DS) and the acceptor (AS) splice sites in the HPV16 genome are indicated as black and white triangles, respectively. The coding potential of each transcript is also indicated.](fcell-08-00474-g004){#F4}

The HPV 16 genome contains three promoters: 1) the early promoter P97 located in the LCR region driving the transcription of early polycistronic RNAs; 2) the late promoter P670 within the E7 ORF driving the expression of late polycistronic transcripts and 3) the recent discovered E8 promoter within the ORF E8, regulating the production of the E8\^E2 transcript which has been demonstrated to control the viral copy number in undifferentiated keratinocytes ([@B206]; [@B36]; [@B228]) ([Figure 4](#F4){ref-type="fig"}).

The HPV gene expression during the viral life cycle is dependent on cellular differentiation stages ([@B59]). Briefly, the E1 and E2 proteins as well as the E6 and E7 proteins are expressed at low levels in the basal cell stratum of the cervical epithelium and become overexpressed once the keratinocytes move from the basal to the mid layers ([@B60]; [@B265]; [@B64]). The L1 and L2 genes, encoding viral capsid proteins, are only produced in the terminally differentiated layers of the cervical epithelium ([@B62], [@B64]). In high grade CIN and cervical cancer the viral genome usually integrates into host genome, causing disruption of the E2 ORF, E6 and E7 up-regulation as well as loss of late proteins expression ([@B46]; [@B177]).

Splicing of HPV16 Transcripts {#S4.SS2}
-----------------------------

The balanced production of HPV16 early and late proteins is necessary for completion of the viral life cycle. The viral polycistronic transcripts are processed by cell splicing factors in order to remove introns through the differential usage of alternative splice sites and the production of viral proteins isoforms ([@B97]). In particular, splicing sites SD226, SD880, SA409, SA526, SA742, SA2582, SA2709, and SA3358 in viral pre-mRNAs generated from the P97 promoter are recognized by the major spliceosome complex of the epithelial cells ([@B111]). The SA3358 is the most used 3′ splice site, since these spliced mRNAs can either be polyadenylated at pA~E~ to generate mRNAs encoding E6, E7, E4, or E5, or polyadenylated at pA~L~ to produce mRNAs encoding L2 structural protein ([@B205]; [@B261]) ([Figures 4B,C](#F4){ref-type="fig"}).

At late stages of productive viral infection, the binding of splicing factors to SD880, SD3632 and SA5639 sites in the transcripts generated from the P670 regulates late splicing events to produce E1\^E4\^L1 mRNAs, encoding both E4 and L1 proteins as well as the E1\^E4 mRNAs ([@B111]).

Alternative splicing plays a major role in the regulation of the HPV16 E6 and E7 oncogene expression. In fact, the E6 and E7 ORFs are transcribed as E6/E7 bicistronic mRNAs that can be spliced into diverse isoforms, such as E6^∗^I, E6^∗^II, E6^∗^III, E6^∗^IV, E6^∗^V, E6^∗^VI, E6\^E7 (E6^∗^X), E6\^E7^∗^I, and E6\^E7^∗^II ([@B5]; [@B24]; [@B173]). Among these, the E6^∗^I and E6^∗^II, resulting from the SD226\^SA409 and SD226\^SA526 splicing, respectively, are the two major E6 isoforms expressed in cervical cancer ([@B283]; [@B3]; [@B30]) ([Figure 4B](#F4){ref-type="fig"}). [@B155] analyzed the E6/E7 mRNA splicing pattern in cell subclones with transformed or differentiated phenotype obtained from the W12 cell line, originally derived from a HPV16-positive low grade cervical lesion ([@B63]). The analysis revealed the concomitant presence of E6, E6^∗^I and E6^∗^II in both transformed and differentiated W12 cell clones. However, the E6^∗^X isoform was only detected in W12 transformed cells, suggesting that the E6/E7 RNA splicing pattern may depend on specific cell transformation stages ([@B155]).

The alternative splicing of viral transcripts is also important to maximize the coding potential of the HPV16 genome. In fact, while the unspliced E6/E7 mRNA encodes for the full length E6 protein, the E6^∗^I and E6^∗^II mRNAs may favor the E7 expression by a termination-reinitiation process or leaky scanning mechanisms and the production of shorter E6 peptides ([@B284]; [@B238]; [@B75]). The E6 and E7 oncoproteins play a major role in cervical carcinogenesis for their ability to abrogate the functions of p53 and pRb oncosuppressors, respectively ([@B162]; [@B243]; [@B268]). Moreover, recent studies showed that the HPV16 E6^∗^I isoform have oncogenic activities, such as the disruption of mitochondrial functions and promotion of ROS production ([@B260]; [@B71]). Such activities are abrogated by the full-length E6 protein suggesting that the HPV-related cell transformation is regulated by the concerted expression of diverse E6 isoforms ([@B179]). Further studies are needed to understand the precise role of viral mRNA splicing processes, especially E6/E7 mRNA, in high grade cervical neoplasia and cervical carcinoma.

The Role of Splicing Factors in HPV RNAs Splicing {#S4.SS3}
-------------------------------------------------

The splicing of HPV RNAs is modulated by cellular hnRNPs and SRSFs factors, that recognize specific enhancer and silencers motifs in the viral transcripts ([@B97]; [@B261]) ([Table 3](#T3){ref-type="table"}).

###### 

Binding motifs recognized by hnRNPs and SRSFs on HPV16 transcripts.

  Splicing factors\*   Binding motifs (5′--3′)   HPV binding regions   References
  -------------------- ------------------------- --------------------- ------------------
  **hnRNPs**                                                           
  hnRNP A1             CAGGGU                    L1                    [@B281]; [@B282]
  hnRNP A2/B1          AUAGUA                    E4                    [@B139]
  hnRNP C              Poly-U                    Early 3′-UTR          [@B55]
  hnRNP D              AUAGUA                    E4                    [@B139]
  hnRNP E1/E2          Poly-C                    L2                    [@B45]
  hnRNP G              CCGAAGAA                  E4                    [@B271]
  hnRNP H              GGG-repeats               L2                    [@B172]
  hnRNP I (PTB)        Poly-U                    Early 3′-UTR          [@B280]
  hnRNP K              Poly-C                    L2                    [@B45]
  hnRNP L              CA-repeats                E4, L1                [@B114]
  **SRSFs**                                                            
  SRSF1                ACCGAAGAA                 E4                    [@B221]
  SRSF3                ACACC, CCACACCAC          E4                    [@B109]
  SRSF9                CCGAAGAA                  E4                    [@B220]

\*Splicing factors whose exact binding site has not been determined yet were not reported in the table.

The hnRNP A1 was shown to favor the production of the E6^∗^I isoform in the absence of EGFR, although its binding site on the E6/E7 transcript has not yet been identified ([@B198]). On the other hand, the hnRNP A1 was shown to bind an ESS in the L1 coding region and to inhibit the production of L1 protein ([@B281], [@B279]; [@B42]; [@B282]) ([Figure 5](#F5){ref-type="fig"}). Recently, [@B4] demonstrated that hnRNP A1 regulates the splicing of HPV18 transcripts by binding to the ESS located at nucleotides 612-639 thus inhibiting the removal of the intron comprised between SD233 and SA416 in the E6/E7 mRNA.

![Splicing regulation of HPV16 mRNAs. Activities of **(A)** hnRNPs and **(B)** SRSFs and their binding motifs on HPV16 transcripts are shown. In particular: red lines indicate silencing activities; green arrows indicate enhancing activities; red sequences are silencing elements; while green sequences are enhancer elements. The donor (SD) and acceptor (AS) splice sites are indicated as black and white triangles, respectively.](fcell-08-00474-g005){#F5}

Similarly, the hnRNP A2/B1 has been shown to mediate the production of the E6^∗^I isoform and to inhibit the splicing at SA5639 by preventing the binding of the U2AF65 splicing factor ([@B198]; [@B114]). Moreover, the hnRNP A2/B1 and hnRNP D factors were demonstrated to bind two AUAGUA motifs located upstream the SD3632 and to inhibit L1 mRNA maturation and protein production in HeLa and C33A2 cervical cancer cell lines transfected with HPV16 complete genome ([@B139]) ([Figure 5](#F5){ref-type="fig"}).

On the other hand, the hnRNP C1 has been demonstrated to increase the L1 and L2 mRNA levels through its binding to the HPV16 early untranslated region and to the AUAGUA silencer upstream the SD3632 in HPV16 -transfected HeLa and C33A cells ([@B55]) ([Figure 5](#F5){ref-type="fig"}). Recently, [@B171] showed that the alkylating cancer drug melphalan induces the inhibition of HPV16 transcripts early poly-adenylation, by inducing hnRNP C interaction with the pA~E~ site, and the expression of HPV16 late gene by inhibiting CPSF30-mediated suppression of the pA~L~.

Furthermore, the hnRNP E1/E2 were shown to interact with hnRNP K and to block the L2 mRNA translation by binding to a *cis*-acting inhibitory sequence located at the 3′-end of the L2 transcript ([@B45]; [@B32]).

The hnRNP G has recently been shown to bind a 8-nucleotide sequence (CCGAAGAA) located downstream the SA3358 in HPV16, thus promoting the production of late mRNAs and skipping of the exon comprised between SA3358 and SD3632 in the L1 mRNA ([@B271]) ([Figure 5](#F5){ref-type="fig"}).

The hnRNP H was shown to promote the polyadenylation at pA~E~ site and to prevent late genes transcription in HeLa cells transfected with sub-genomic HPV16 plasmids through its interaction with the cut stimulating factor (CStF-64) and with G-rich motifs located in the L2 ORF ([@B172]) ([Figure 5](#F5){ref-type="fig"}). The late protein L1 was shown to interact with hnRNP H and to activate late genes transcription in differentiated keratinocytes ([@B285]).

The hnRNP I binds a U-rich region in the 3′-UTR of HPV16 genome and induces L1/L2 mRNAs production by interfering with a polyadenylation signal at the pA~E~ and with splicing inhibitory elements located upstream and downstream the SD3632 ([@B280]; [@B222]) ([Figure 5](#F5){ref-type="fig"}).

[@B114] showed that the hnRNP L phosphorylation by Akt causes its association with HPV16 late splice sites (SA3358, SD3632) and pA~E~, the inhibition of U2AF65 binding and decreased L1 mRNA production. Accordingly, the siRNA mediated knockdown of hnRNP L restored the expression of HPV16 L1 and L2 proteins confirming the this splicing factor performs a fine tuning of HPV16 late transcripts ([@B114]) ([Figure 5](#F5){ref-type="fig"}).

The SRSF1 factor has been shown to bind the 8-nucleotide purine-rich enhancer downstream the SA3358 site in the E4 ORF and to activate the splicing of early transcripts (except E1 and E2) as well as late mRNAs in different phases of the viral life cycle ([@B200]; [@B157]; [@B221]; [@B138]) ([Figure 5](#F5){ref-type="fig"}). In addition, the SRSF1 is able to bind the exon between SA3358 and SD3632 sites causing partial inhibition of the splicing at SA3632 and production of L1 mRNAs ([@B221]). The SRSF1 has also been shown to reduce the splicing at SA2709 causing inhibition of E2 mRNA production while favoring production of E6 and E7 transcripts in the early phases of HPV16 life cycle ([@B221]).

The SRSF2 and SRSF3 factors promote the early viral transcripts maturation, while their knockdown induces a strong reduction of E6 mRNA isoforms and E6 and E7 oncoproteins expression in CaSki cell lines ([@B155]; [@B122]). Interestingly, the transcriptional activity of the P97 promoter was not affected by SRSF2 levels suggesting it may favor the accumulation of E6/E7 RNAs by regulating the nonsense mediated decay ([@B155]). In addition, SRSF3 depletion causes reduction of E4/L1 mRNA and L1 protein production in W12E cells ([@B155]; [@B122]). Moreover, the SRSF3 is able to bind an A/C-rich enhancer downstream the SA3358 and to promote early genes expression and polyadenylation while inhibiting the late genes expression in CaSki and HeLa cells ([@B200]; [@B109]) ([Figure 5](#F5){ref-type="fig"}).

The SRSF9 was also shown to inhibit the HPV16 SA3358 enhancer and to promote the production of L1 mRNAs through the skipping of the exon between SA3358 and SD3632 sites as well as through the activation of the splicing at SA5639 ([@B220]) ([Figure 5](#F5){ref-type="fig"}).

Finally, the cooperation of Sam68 and Brm has been shown to promote the production of full-length E6/E7 transcripts following the activation of Sam68 by Erk1/2 kinase in the presence of EGF in E6-transfected immortalized foreskin keratinocytes ([@B198]).

HPV Proteins and Cell Splicing Factors {#S4.SS4}
--------------------------------------

The HPV E2 protein has been shown to possess SRSF-like activities and to regulate viral transcription and replication thus playing a key role in the HPV life cycle ([@B103]; [@B96]). An interactome analysis showed that E2 protein binds to several RNA processing proteins and spliceosome components, such as EFTUD2, EIF4A3, SRPK1 and SRPK2, suggesting that it may be involved in the mRNA maturation processes ([@B105]). [@B20] showed that E2 binds to SA408 in the E6/E7 pre-mRNA and interacts with SRSF5, SRSF4, SRSF6 and SRSF9 through its C-terminal domain causing intron 1 exclusion from E6 and E7 mRNAs. Moreover, in mid layers HPV infected keratinocytes the levels of E2 correlate with the expression of SR proteins and both of them increase in cervical neoplasia during CIN progression from grade 1 to grade 3 ([@B48]).

On the other hand, chromatin immunoprecipitation assays showed that E2 binds a region comprised between nucleotides 565-363 upstream the SRSF1 AUG starting site through its N-terminal domain and transactivates the SRSF1 expression in the U2OS human osteosarcoma cell line ([@B161]). The E2 protein has also been shown to highly transactivate the SRSF3 promoter in the E2-gene transfected U2OS cells ([@B122]). [@B159] recently observed that E2-transfected keratinocytes showed an increased expression of SRPK1 and hyper-phosphorylation of SRSF1, that translocate from the nucleus to the cytoplasm in a keratinocyte differentiation-specific manner.

Furthermore, the HPV16 E6 oncoprotein was demonstrated to interact with SRSF4, SRSF6, SRSF9 and with the E6/E7 pre-mRNA promoting intron 1 retention through a NLS3 sequence localized within its C-terminal domain ([@B20]).

In HPV infected cells the release of E2F1 transcription factor, caused by the E7 binding to pRb, and its recruitment to binding sites in the SRSF10 promoter region determined increased expression of SRSF10 ([@B144]). Accordingly, the silencing of E6/E7 mRNA was shown to cause downregulation of SRSF10 in cervical cancer as well as in cervical cancer cell line SiHa ([@B144]).

Splicing Factors Deregulation in Cervical Cancer {#S4.SS5}
------------------------------------------------

The hnRNPs and SRSFs are generally upregulated in the basal and middle layers of the cervical epithelium and are downregulated in the terminal differentiated layers, while several of them have been found hyper-expressed in cervical carcinoma and suggested to play important roles in cervical carcinogenesis ([@B72]; [@B111]).

In particular, the hnRNP A1 is significantly overexpressed either in high grade CIN or in cervical carcinoma compared to normal cervical epithelium representing a candidate diagnostic biomarker of cervical cancer ([@B121]; [@B193]). Interestingly, a transcriptome analysis of HPV16 E6 and E7 immortalized epithelial cells showed up-regulation of hnRNP A1 in cells cultured under hypoxic condition, suggesting that its expression could be induced by stress ([@B53]). The hnRNP A1 facilitates the production of mature miR-18a thus promoting proliferation and invasion of SiHa cells ([@B58]). The miR-18a suppresses the expression of PTEN, WNK2, SOX6, BTG3, and RBSP3 genes by binding to their 3′-UTR transcripts, and causes PD-L1 expression and Wnt/β-catenin pathway activation in cervical carcinoma ([@B58]). Moreover, the siRNA-mediated hnRNP A1/A2 knockdown caused shortening of telomeres, procaspase-3 and PARP cleavage as well as increased apoptosis in HeLa cells, suggesting that it plays a significant role in cervical cancer cell viability ([@B187]).

The role of hnRNP A2/B1 in cervical cancer has been recently investigated ([@B140]). Interestingly, [@B140] observed that lobaplatin induced cell cycle arrest and apoptosis via downregulation of hnRNP A2/B1 in Caski cells. Moreover, the hnRNP A2/B1 knockdown was shown to suppress cell proliferation, migration and invasion, while increasing the apoptosis and the sensitivity to irinotecan or lobaplatin through the up-regulation of p21, p27 and cleaved caspase-3 as well as p-AKT down-regulation in HeLa and CaSki cell lines ([@B209]).

The hnRNP E1 and E2 expression decreases during the progress from low grade to high grade cervical neoplasia with an inverse correlation with HPV16 E6 protein levels ([@B189]). Indeed, both factors may act as oncosuppressors, being under-expressed in CIN 2-3 and cervical carcinoma compared to CIN 1 ([@B86]).

[@B239] demonstrated that hnRNP F binds to a GGGA ESS motif, located within ENOX2 exon 4, causing enhanced production of ENOX2 exon 4 minus splicing variant, that is overexpressed in cervical cancer and involved in increased cell growth.

The levels of hnRNP H and I are higher in cervical cancer and high grade CIN compared to low grade CIN and normal tissues ([@B172]; [@B72]). The hnRNP I knockdown reduces the proliferation and anchorage-independent growth while increasing invasiveness of HeLa cells ([@B253]). The hnRNP I was also shown to regulate gene expression by forming a dimer with PTB-associated splicing factor (PSF) in SiHa and CaSki cells ([@B275]). Moreover, [@B275] demonstrated that lncRNA ARAP1-AS1 interacts with PSF causing the release of hnRNP I, which in turns enhances the c-Myc IRES-dependent translation by binding to c-Myc mRNA 5′-UTR enhancing SiHa and Caski cell proliferation.

The hnRNP P2 (FUS/TLS) is highly expressed in cervical cancer as well as in SiHa and HeLa cells, dependently from the activation of XIST lncRNA/miR-200a axis, and induces the epithelial mesenchymal transition phenotype and proliferation while inhibiting apoptosis in cervical cancer cells ([@B291]).

The SRSF1, SRSF2 and SRSF3 proteins are overexpressed in CIN 1 upper differentiated layers, in the CIN3 entire epithelium as well as in W12 cells ([@B160]). The SRSF1 down-regulation causes the caspase 9a/9b decreased ratio and increased sensitivity of cancer cells to DNA damaging agents ([@B214]). Similarly, the SRSF2 depletion causes increased p53 expression and apoptosis in W12 transformed subclones as well as decreased anchorage-independent growth and cell cycle arrest at G2/M checkpoint both in W12 and C33A cells ([@B155]). [@B262] first demonstrated that SRSF1 was able to bind to CGGACAC motifs in the pri-miR-7-1, pri-miR-221 and pri-miR-222 stem loops thus enhancing Drosha cleavage and accumulation of miR-7, miR-221 and miR-222, promoting cervical cancer development ([@B180]). Moreover, [@B57] demonstrated that the lncRNA MIR205HG, which is overexpressed in cervical cancer, targets SRSF1 and up-regulates KRT17 causing cell proliferation and apoptosis inhibition in CaSKi, Hela, MS751 and SiHa cells. The silencing of SRSF3 in HeLa cells was shown to promote the production of ILF3 isoforms 1 and 2 as well as cell cycle progression to the S and G2/M phases and proliferation enhancement ([@B107]). In addition, a miRNA array analysis showed that SRSF3 knockdown in HeLa cells caused the down-regulation of miR-16, miR-18a, miR-21, miR-92b, miR-128, miR-182, miR-629, miR-629, miR-1180, and miR-1308, and the up-regulation of miR-7, miR-26a, miR-30a, miR-99a, miR100, miR-125b, miR-181a, miR-206, miR-378, and miR-923, all involved in carcinogenic processes ([@B2]; [@B244]).

The SRSF9 is overexpressed in cervical carcinoma, due to the down regulation of miRNA-802 that in normal epithelium binds the 3′-UTR region of SRSF9 transcript inhibiting translation, and causes increase in cell proliferation ([@B273]).

Similarly, the SRSF10 is increasingly overexpressed in CIN and cervical cancer cells. Its expression is higher in HPV16 and HPV18-positive compared to HPV-negative cervical cancers, but becomes strongly downregulated following the E6/E7 silencing in CaSki cells ([@B144]). Moreover, the injection of SRSF10-knockdown SiHa cells in nude mice reduced tumor growth suggesting that this factor promotes cell proliferation ([@B144]). The overexpression of SRSF10 has shown to favor the transcription of the CD47 immune evasion signal and the production of the mIL1RAP isoform, which induces the NF-κB activation and the IL-1β signal transduction associated with production of pro-inflammatory cytokines ([@B144]).

Finally, the SRSF11 (SRp54) has been observed to interact with TERC and TRF2 factors and to promote the telomerase association with telomeric repeats and telomeres elongation in HeLa cells ([@B132]).

Other Splicing Factors in Cervical Cancer {#S4.SS6}
-----------------------------------------

Other proteins involved in splicing processes, including Tra2β, Brm and Sam68, have been found deregulated in cervical cancer and derived cell lines and proposed to have significant roles in cervical carcinogenesis. Specifically, the over expression of Tra2β protein, which localizes to the cervical carcinoma cell nuclei, was demonstrated to correlate with lymph node metastasis, higher tumor grade, size and depth of invasion ([@B82]; [@B18]). The Brm factor is able to interact with ERK phosphorylated Sam68 causing the production of the CD44v5 variant by its direct binding to the exon 5 splice-regulatory elements and exon 5 retention in CD44 mRNA in HeLa cell line ([@B59]).

The Sam68 is highly expressed in cervical carcinoma and its cytoplasmic localization is shown to be associated with pelvic lymph node metastasis and poor prognosis in patients with early-stage cervical cancer ([@B141]). [@B141] also demonstrated that down-regulation of Sam68 in cervical cancer cells reduced the cell motility and invasion as well as reversed the epithelial mesenchymal transition phenotype through the inhibition of the Akt/GSK-3β/Snail pathway. In HeLa cells the Sam68 was shown to bind a UAAAAAGCAU sequence within the exon 3 of survivin mRNA thus promoting the production of the anti-apoptotic DEx3 variant. Such variant has been found over-expressed in cervical adenocarcinoma HeLa cell line as well as in cervical carcinoma tissues ([@B81]; [@B88]). Moreover, Sam68 was observed to interact with SRm160, a SR-rich splicing co-activator, to stimulate the inclusion of the v5 exon into the CD44 mRNA in a Ras-signaling dependent manner causing increased invasiveness of HeLa cells ([@B40]).

Splicing-Targeted Therapeutic Strategies {#S4.SS7}
----------------------------------------

The relevant role of aberrant splicing in carcinogenesis highlights the need for novel splicing-targeted therapies. Currently, different strategies have been adopted to target deregulated splicing factors and abnormal splicing variants, including the usage of small bacteria-derived molecules against the core spliceosome, splicing regulators inhibitors and anti-sense oligonucleotides against oncogenic mRNA isoforms ([@B133]; [@B15]; [@B143]; [@B56]; [@B21]) ([Table 4](#T4){ref-type="table"}).

###### 

Splicing-targeted strategies.

  Splicing-targeted strategies                         Molecules                             Targets                                                                                                      Activity                                                                                                                                References
  ---------------------------------------------------- ------------------------------------- ------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------
  Bacteria-derived compounds                           Spliceostatins                        SF3b                                                                                                         Inhibition of spliceosome assembly, splicing disruption and cell cycle arrest                                                           [@B113]; [@B272]
                                                       Pladienolides                                                                                                                                                                                                                                                                              
  Splicing regulators inhibitors                       SPHINX, SRPIN340                      SRPK1                                                                                                        Reduced phosphorylation, altered localization and activity of SRSFs                                                                     [@B147]; [@B9]; [@B153]; [@B31]; [@B176]
                                                       Cpd-1, Cpd-2, Cpd-3                   Clk1, Clk2                                                                                                                                                                                                                                           
                                                       Resveratrol, caffeine, theophylline   hnRNPs and SRSFs mRNAs                                                                                       Inhibition of hnRNPs and SRSFs expression, rescuing of aberrant splicing events and reduction of cell proliferation                     
  Splice-switching antisense oligonucleotides (SSOs)   2′-*O*-methylated SSO                 Splicing factors binding sites (i.e., splicing acceptor and donor sited, splicing enhancers and silencers)   Inhibition of splicing factors interaction with binding sites by steric hindrance and reduction of oncogenic mRNA isoforms production   [@B17]; [@B158]
                                                       2′-*O*-methoxyethylated SSO                                                                                                                                                                                                                                                                

Several bacterial derived small molecules or their synthetic analogs have been used to inhibit the spliceosome assembly or the post-translational modifications of the core spliceosome components ([@B67]). Particularly, spliceostatins and pladienolides derived from *Pseudomonas* and *Streptomyces*, respectively, have shown to bind the SF3b component of U2 snRNP causing the inhibition of the spliceosome assembly and cell cycle arrest at G1 and G2/M phases ([@B166]; [@B202], [@B201]). The binding of spliceostatin A to SF3b1 has been demonstrated to stimulate the production of unspliced p27 mRNA encoding the C-terminal truncated p27^∗^ variant which causes cell cycle arrest at G1 phase by inhibiting CDK2 in HeLa cells ([@B113]; [@B203]). Treatment with pladienolide B caused reduction of SF3b1 expression in a dose-dependent manner, cell cycle arrest at the G2/M phase and induction of apoptosis by increasing the expression of Tap73, cytochrome C and pro-apoptotic Bax, while decreasing the levels of ΔNp73 and anti-apoptotic Bcl-2 in HeLa cells ([@B272]).

Targeting of kinases regulating the splicing factors activity, such as SRPK1 and CLK2, represents a further promising therapeutic model ([@B247]). Either SRPK1 siRNA knockdown or treatment by SPHINX and SRPIN340 inhibitors reduced the SRSF1, SRSF2 and SRSF5 phosphorylation causing increased production of the anti-apoptotic VEGF165b isoform in PC-3 prostate cancer cell line ([@B153]). [@B9] showed that Cpd-1, Cpd-2, and Cpd-3 compounds inhibit the Clk1 and Clk2 kinases activity causing reduction of SRSF4 and SRSF6 phosphorylation and modifying genome-wide splicing patterns. In particular, the transcriptome analyses performed after treatment with Cpd-2 showed changes in the splicing patterns of gene transcripts involved in growth and survival, such as EGFR, CD44, EIF3H, AURKA, HDAC1, and PARP, leading to reduced proliferation and increased apoptosis in colorectal cancer COLO205 and COLO320DM, lung cancer NCI-H23 as well as breast cancer MDA-MB-468 cell lines ([@B9]).

Splice-switching antisense oligonucleotides (SSOs) are synthetic 15--30 nucleotide long sequences that bind matched splice sites and inhibit the splicing factors interaction by steric hindrance ([@B102]). Chemical modifications, such as 2′-*O*-methylation and 2′-*O*-methoxyethylation are necessary to prevent degradation of pre-mRNA-SSO complexes by RNase H ([@B195]). The 2′-*O*-methoxyethylated Bcl-x SSO oligonucleotide is able to target the 5′-splice site in exon 2 of Bcl-x mRNA causing switch from anti-apoptotic Bcl-xL to pro-apoptotic Bcl-xS in a dose dependent manner and apoptosis via PARP cleavage in B16F10 mouse melanoma cells ([@B17]). Furthermore, 2′-*O*-methylated SSO, targeting the 3′-splice site in exon 14b of MKNK2 mRNA, enhances the tumor-suppressor Mnkn2a isoform levels, leading to increased phosphorylation and activation of p38α--MAPK and overexpression of cFOS, COX2 and IL-6 target genes ([@B158]). The treatment with 2′-*O*-methylated SSO causes reduction of anchorage independent growth and survival in glioblastoma U87MG, hepatocellular carcinoma HuH7 and breast cancer MDA--MB--231 cell lines ([@B158]).

The resveratrol has been shown to regulate the miR-424 and miR-503 expression that inhibit hnRNP A1 production and cell proliferation in human breast cancer cell line MCF7 ([@B176]). In addition, bortezomib has found to reduce the expression of hnRNP K, hnRNP H, Hsp90α, Grp78, and Hsp7C in Burkytt lymphoma cell lines such as CA46 and Daudi, as determined by a proteomic analysis ([@B230]).

A natural compound, caffeine, was demonstrated to reduce the SRSF3 levels by causing increased expression of the p53β variant, reduced expression of SRSF3 targets, such as HIF-1α, SREBP1c, COX-2, FASN, and EGFR, and enhanced cell senescence ([@B147]). Similarly, theophylline down-regulates SRSF3 expression and switches the production from p53α to p53β isoform in HeLa and MCF-7 cell lines causing apoptosis, senescence, and decreased colony formation ([@B31]). Another natural drug namely indacaterol was shown to rescue SRSF6 associated aberrant splicing events, such as ZO-1 exon 23 skipping, and to reduce the viability of RKO, HCT116, and HCT8 colorectal cancer cells as well as to inhibit cancer growth in a colorectal cancer mouse model ([@B251]).

Aberrant protein isoforms have also been proposed as potential therapeutic targets ([@B131]). A comprehensive genomic analysis of 38'028 tumors allowed the discovery of recurrent somatic mutations in the splice donor and acceptor sites in MET transcripts causing skipping of exon 14 in lung adenocarcinoma ([@B76]). The expression of exon 14-lacking MET in NIH3T3 cells conferred higher sensitivity to MET-specific inhibitors, such as capmatinib, compared to cells expressing wild type MET ([@B76]).

Conclusion {#S5}
==========

In recent years, there is a growing experimental evidence of the key role played by deregulated splicing in cancer development and progression. Several genome-wide studies have revealed tumor specific splicing profiles at mRNA and protein level, identifying a multitude of aberrant splice variants with oncogenic functions. Different protein isoforms have been demonstrated to have a prognostic value and to modify the sensitivity of cancer cells to chemotherapeutic agents. On the other hand, therapies targeting deregulated splicing factors or pathogenic splicing isoforms are under development. Several data have been published on the role of splicing factors in cervical cancer development and further studies are needed to clarify the relevance of such factors in the production of viral or cell genome encoded oncogenic isoforms as well as in the promotion of pre-neoplastic lesions progression to invasive cancer. Much more needs to be done for the development and the clinical application of splicing-targeted therapeutic agents that would inhibit cervical cancer as well as other HPV-related tumors by affecting both cell oncogenic pathways as well as HPV life cycle.
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:   BCL2 associated transcription factor 1
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:   early onset
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:   intronic splicing enhancer

ISS
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:   micro-RNA
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:   matrix metallopeptidase 3
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:   mechanistic target of rapamycin kinase
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NEK2
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NLS

:   nuclear localization signal
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:   non-sense mediated decay
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:   early/late polyadenylation signal
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:   proliferating cell nuclear antigen
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